Israel Englander’s Janux Therapeutics JANX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.75M Buy
504,544
+117,734
+30% +$1.71M ﹤0.01% 2569
2026
Q1
$5.38M Buy
386,810
+97,002
+33% +$1.33M ﹤0.01% 2854
2025
Q4
$4M Buy
289,808
+189,163
+188% +$4.45M ﹤0.01% 3263
2025
Q3
$2.46M Sell
100,645
-113,717
-53% -$2.77M ﹤0.01% 3847
2025
Q2
$4.95M Buy
214,362
+132,089
+161% +$3.48M ﹤0.01% 3012
2025
Q1
$2.22M Sell
82,273
-33,829
-29% -$1.28M ﹤0.01% 3679
2024
Q4
$6.22M Buy
+116,102
New +$6.14M ﹤0.01% 2626
2024
Q2
Sell
-5,784
Closed -$272K 6226
2024
Q1
$218K Sell
5,784
-66,072
-92% -$1.44M ﹤0.01% 5328
2023
Q4
$771K Sell
71,856
-28,756
-29% -$249K ﹤0.01% 4346
2023
Q3
$1.01M Sell
100,612
-37,634
-27% -$434K ﹤0.01% 4175
2023
Q2
$1.64M Buy
138,246
+104,143
+305% +$1.39M ﹤0.01% 3651
2023
Q1
$413K Sell
34,103
-5,807
-15% -$96.6K ﹤0.01% 4717
2022
Q4
$526K Buy
+39,910
New +$584K ﹤0.01% 4709
2021
Q3
Sell
-75,257
Closed -$1.88M 7020
2021
Q2
$1.88M Buy
+75,257
New +$1.68M ﹤0.01% 4039

Other funds holding JANX

Israel Englander's JANX Position: Q2 2026 in Review

Israel Englander increased its Janux Therapeutics (JANX) stake by 30% in Q2 2026, buying an estimated $1.71M and bringing the position to 504,544 shares worth $7.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2569.

Israel Englander first reported a position in JANX in Q2 2021 and has held it in 14 quarters since. 196 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Israel Englander held 504,544 shares of Janux Therapeutics worth $7.75M as of Q2 2026.
  • Israel Englander bought 117,734 Janux Therapeutics shares in Q2 2026, an estimated $1.71M.
  • Janux Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2569 holding.
  • Israel Englander first reported a position in Janux Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • 196 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.